Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa/IIb comparison of recombinant human rabies immunoglobulin versus human rabies immunoglobulin with or without rabies vaccine
ChiCTR1900023236Phase 2Completed
- Sponsor
- Chaoyang District Center for Disease Control and Prevention
- Start
- Apr 2015
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ormutivimab, rabies immune globulin (human) and human rabies vaccine in rabies (7 arms), sponsored by Chaoyang District Center for Disease Control and Prevention. Primary endpoints: Rabies virus neutralizing antibody activity and Safety. Started Apr 2015; status: completed.
02
Drugs
ormutivimabrabies immune globulin (human)human rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR1900023236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023236.